BD’s Vacutainer UltraTouch Push Button Blood Collection Set launched in the U.K.

BD (Becton, Dickinson and Company) has launched a new safety blood collection set—the BD Vacutainer UltraTouch Push Button Blood Collection Set—in the United Kingdom after receiving CE marking.
 
The BD Vacutainer UltraTouch Push Button Blood Collection Set employs patented PentaPoint Comfort five-bevel needle technology which helps enhance the patient experience during the blood collection procedure. The PentaPoint technology has previously been used in the BD Pen insulin injection needles and studies have shown that this design helps reduce the chance of a painful injection by creating a flatter, thinner surface to help penetrate the skin with significantly greater ease.¹
 
In addition, the device uses BD RightGauge ultra-thin wall technology, which increases the needle’s inner diameter without impacting the strength of the needle. This enables clinicians to select a smaller gauge needle to enhance the patient experience and aid in difficult venous access, without sacrificing sample quality or tube-fill time, according to the company. By utilizing both the BD RightGauge and BD PentaPoint technologies, the BD Vacutainer UltraTouch Push Button Blood Collection Set has been shown to decrease penetration forces by up to 32 percent when compared to another leading blood collection set.² The device also delivers proven protection to healthcare professionals who perform the blood draw procedures from costly needlestick injuries, with its split-second in-vein retractable safety needle.
 
“Phlebotomy is often one of the first procedures hospital patients undergo and it can set the tone for their entire experience,” said Mike Fairbourn, vice president and general manager, United Kingdom and Ireland, at BD. “The combination of BD’s latest technology will both reduce patient pain and improve clinicians’ ability to access difficult veins, enhancing the experience for all involved. With the BD Vacutainer UltraTouch Push Button Blood Collection Set, clinicians can select the gauge that is most appropriate for their patients, without compromising sample quality, testing accuracy or their own efficiency.”
 
Franklin Lakes, N.J.-based BD develops solutions that help advance medical research and genomics, enhance the diagnosis of infectious disease and cancer, improve medication management, promote infection prevention, equip surgical and interventional procedures, optimize respiratory care and support the management of diabetes. BD has more than 45,000 associates across 50 countries.
 
References:
1. Hirsch L.J., et al. Journal of Diabetes Science and Technology. 2012, 6(2):328-35.
2. 2015 BD bench testing versus BD Vacutainer Push Button Blood Collection Sets.